Literature DB >> 1540899

Somatic mutations and human breast cancer. A status report.

R Callahan1, C S Cropp, G R Merlo, D S Liscia, A P Cappa, R Lidereau.   

Abstract

A systematic study of primary human breast tumor DNA demonstrated that three proto-oncogenes or regions of the genome (c-myc, int-2, and c-erbB2) are frequently amplified and that there is loss of heterozygosity (LOH) on chromosomes 1p(37%), 1q(20%), 3p(30%), 7(41%), 11p(20%), 13q(30%), 17p(49%), 17q(29%), and 18q(34%). Specific subsets of tumors can be defined based on the particular collection of mutations they contain. For instance, LOH on chromosomes 11p, 17p, and 18q frequently occurs in the same tumor. A search for putative tumor suppressor genes within the regions of the genome affected by LOH has been started. In a comprehensive molecular analysis of the p53 gene on chromosome 17p, 46% of the tumors contained a point mutation in the p53 gene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540899     DOI: 10.1002/1097-0142(19920315)69:6+<1582::aid-cncr2820691313>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Expression of the novel human gene, UBE2Q1, in breast tumors.

Authors:  Atefeh Seghatoleslam; Mohsen Nikseresht; Sayed Mohammad Shafiee; Ahmad Monabati; Mohammad Mehdi Namavari; Abdolrassul Talei; Akbar Safaei; Ali Akbar Owji
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

2.  Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18.

Authors:  Karen A Gould; Martin Tochacek; Beverly S Schaffer; Tanya M Reindl; Clare R Murrin; Cynthia M Lachel; Eric A VanderWoude; Karen L Pennington; Lisa A Flood; Kimberly K Bynote; Jane L Meza; Michael A Newton; James D Shull
Journal:  Genetics       Date:  2004-12       Impact factor: 4.562

3.  When considering attacks against the National Breast Screening Study, consider the sources.

Authors:  B Goldman
Journal:  CMAJ       Date:  1993-02-01       Impact factor: 8.262

4.  Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.

Authors:  K Segers; H Backhovens; S K Singh; J De Voecht; M Ramael; C Van Broeckhoven; E Van Marck
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 5.  Molecular biology of testicular germ cell tumors: current status.

Authors:  B Schmidt; R Ackermann; T Strohmeyer
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

Review 6.  Studying environmental influences and breast cancer risk: suggestions for an integrated population-based approach.

Authors:  R Millikan; E DeVoto; B Newman; D Savitz
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

7.  The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology.

Authors:  B Newman; P G Moorman; R Millikan; B F Qaqish; J Geradts; T E Aldrich; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

8.  (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer.

Authors:  J C Zenklusen; I Bièche; R Lidereau; C J Conti
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

9.  Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes.

Authors:  Betsy J Barnes; Merrill J Kellum; Ann E Field; Paula M Pitha
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.

Authors:  R Moll; M Mitze; U H Frixen; W Birchmeier
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.